Conceptio
›
Archive
›
NCBI PubMed Central
NCBI PubMed Central
open access
Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.
Kuppens GZL et al.
NCBI PubMed Central · Papers · License: Open Access
Open Source ↗
Direct PDF ↓
dataprotectionlawgdpr
data protection law GDPR
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record
· ID 469192
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.